The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests. The drug, ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due ...

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings. Giving obese children weight-loss ...

Health experts presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...